Elevated neutrophil‐to‐lymphocyte ratio predicts poor outcome in patients with advanced non‐small‐cell lung cancer receiving first‐line gefitinib or erlotinib treatment

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles